These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31030578)

  • 21. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Key pharmacovigilance stakeholders' experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union.
    Inácio P; Cavaco A; Allan E; Airaksinen M
    Public Health; 2018 Feb; 155():119-128. PubMed ID: 29346070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient involvement in pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France.
    Adopo D; Daynes P; Benkebil M; Debs A; Jonville-Berra AP; Polard E; Micallef J; Maison P
    Eur J Clin Pharmacol; 2023 Feb; 79(2):229-236. PubMed ID: 36508012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Patient Adverse Drug Reaction Reporting Systems in Nine Selected Countries.
    Worakunphanich W; Youngkong S; Suwankesawong W; Anderson C; Thavorncharoensap M
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacovigilance implemented by patients: A necessity in the 21st century.
    Lafond J
    Therapie; 2016 Apr; 71(2):245-7. PubMed ID: 27080846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse drug reaction reporting in the Czech Republic 2005-2009.
    Kopečná E; Deščíková V; Vlček J; Mladá J
    Int J Clin Pharm; 2011 Aug; 33(4):683-9. PubMed ID: 21678040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.
    Härmark L; van Hunsel F; Grundmark B
    Drug Saf; 2015 Apr; 38(4):337-47. PubMed ID: 25627832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
    Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
    Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study.
    de Vries ST; Denig P; Ekhart C; Burgers JS; Kleefstra N; Mol PGM; van Puijenbroek EP
    Br J Clin Pharmacol; 2019 Jul; 85(7):1507-1515. PubMed ID: 30941789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.
    Liu F; Jagannatha A; Yu H
    Drug Saf; 2019 Jan; 42(1):95-97. PubMed ID: 30649734
    [No Abstract]   [Full Text] [Related]  

  • 36. The Impact of Experiencing Adverse Drug Reactions on the Patient's Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands.
    Rolfes L; van Hunsel F; Taxis K; van Puijenbroek E
    Drug Saf; 2016 Aug; 39(8):769-76. PubMed ID: 27145946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?
    Kheloufi F; Default A; Rouby F; Laugier-Castellan D; Boyer M; Rodrigues B; Ponte-Astoul J; Jean-Pastor MJ; Blin O; Micallef J
    Eur J Clin Pharmacol; 2017 Aug; 73(8):1009-1018. PubMed ID: 28391408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
    Matos C; van Hunsel F; Joaquim J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse Drug Reaction Reporting by Patients in 12 European Countries.
    Valinciute-Jankauskiene A; Kubiliene L
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33562536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.